8-K filed Aug 5, 2026 at 06:33 ET
United Therapeutics reported Q2 2026 revenue of $783.3M, down 2% YoY and below the $804.6M consensus, while diluted EPS of $7.27 beat the $6.86 estimate by 5.9%. The revenue miss was driven by a 4% decline in total Tyvaso sales as Nebulized Tyvaso dropped 18% YoY, partially offset by Tyvaso DPI growth. Net income rose 8% YoY to $333.0M, benefiting from a lower effective tax rate (11% vs 24%) and the absence of a prior-year $21.7M PPE impairment. The company highlighted recent NDA submissions for ralinepag (PAH) and Nebulized Tyvaso (IPF) as key pipeline catalysts, but the top-line decline and competitive headwinds in the inhaled prostacyclin class temper the outlook.